-
CTI 2024丨Dr. Edmund K. Waller Explores VIP-Mediated Immune Checkpoint Pathways
Key Highlights Q1: Could you briefly introduce the current research landscape in cancer immunotherapy, particularly in novel immune checkpoint pathways, and why you chose this area as your focus? Dr.…
-
Dr. Cheng Huang: Overview of Landmark Advances in Innovative Drugs for Lung Cancer in 2024
Oncology Frontier: The 2024 Elite Lung Cancer Symposium has successfully concluded. As the conference chair, could you share the key highlights of this event? Dr. Cheng Huang: The 2024 Elite…
-
Dr. Shusen Wang: Exploration and Breakthroughs in Endocrine Therapy for Advanced Breast Cancer | Northern Breast Cancer Salon Annual Progress Review
The “Northern Breast Cancer Salon Annual Progress Review” was held in Beijing from January 3 to 5, 2025, providing a comprehensive overview of the latest developments in the diagnosis, treatment, and research of breast cancer over the past year. Dr. Shusen Wang from the Sun Yat-sen University Cancer Center presented a summary of the advances…
-
Dr. Jin Yang: Advances in Endocrine Therapy for Early Breast Cancer – Precision Medicine Opportunities and Challenges
Oncology Frontier: Could you briefly summarize the important advances in endocrine therapy for early breast cancer in 2024? Dr. Jin Yang: Overall, the progress in endocrine therapy for HR+/HER2- early…
-
Annual Review | Dr. Changli Wang: Advances and Future Perspectives in Perioperative Immunotherapy for NSCLC in 2024
In recent years, immunotherapy drugs, particularly PD-1/PD-L1 inhibitors, have gradually expanded from being used in later-line treatments to frontline therapy for non-small cell lung cancer (NSCLC). Perioperative immunotherapy has become a major focus in the field, with numerous breakthroughs reshaping the treatment landscape for operable NSCLC patients. However, challenges remain in patient selection, treatment regimens,…
-
Annual Review | Dr. Yongmei Yin: Advances in HER2-Positive Breast Cancer Research in 2024
As 2024 concludes, the year has left us with significant milestones and breakthroughs in oncology. Oncology Frontier invited Dr. Yongmei Yin from Jiangsu Cancer Hospital to summarize the year’s advancements in HER2-positive breast cancer research, highlighting the clinical transformations brought by innovative therapies.
-
Dr. Yan Wang Discusses Advances in Research on Rare Mutations in NSCLC in 2024 | 2024 Academic Conference on Precision Diagnosis and Treatment of Lung
Oncology Frontier: With the progress in the precise diagnosis of lung cancer, many rare/rare gene mutations have been discovered. First, could you briefly introduce the current hottest rare targets? Dr.…
-
Gut | Aspirin Use Lowers Pancreatic Cancer Risk and Mortality in Type 2 Diabetes Patients
Pancreatic cancer (PC) stands as one of the most lethal cancers globally, ranking 12th in prevalence and sixth in cancer-related deaths. Its aggressive nature and often late diagnosis contribute to a dismal 5-year survival rate of merely 12%. While surgical resection offers the only potential cure, most patients are diagnosed at advanced stages, rendering surgery…
Connecting Medical Expertise through Media